OPEN END TURBO OHNE STOP-LOSS - ASTRAZENECA | Delayed Börse Stuttgart 02:09:01 2024-06-25 EDT | ||
| 6.37 EUR | +0.47% |
|
| 1 month | +3.07% | ||
| 3 months | +56.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 6.37 | +0.47% |
| 24-06-24 | 6.34 | +1.60% |
| 24-06-21 | 6.24 | +0.48% |
| 24-06-20 | 6.21 | +0.16% |
| 24-06-19 | 6.2 | -2.67% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 02:09 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Lang & Schwarz |
| WKN | LS8P80 |
| ISIN | DE000LS8P809 |
| Date issued | 2020-12-02 |
| Strike | 84.56 € |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.28 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.6 € |
|---|---|
| Lowest since issue | 0.17 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159
USD
Average target price
174.4
USD
Spread / Average Target
+9.68%
- Stock Market
- Certificates
- Certificat
